CYPHERPUNK TECHNOLOGIES INC (CYPH) Stock Price & Overview
NASDAQ:CYPH • US52187K2006
Current stock price
The current stock price of CYPH is 1.06 USD. Today CYPH is up by 6.11%. In the past month the price increased by 75.79%.
CYPH Key Statistics
- Market Cap
- 95.379M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.84
- Dividend Yield
- N/A
CYPH Stock Performance
CYPH Stock Chart
CYPH Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CYPH.
CYPH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CYPH. CYPH has a great financial health rating, but its profitability evaluates not so good.
CYPH Earnings
CYPH Forecast & Estimates
CYPH Groups
Sector & Classification
CYPH Financial Highlights
Over the last trailing twelve months CYPH reported a non-GAAP Earnings per Share(EPS) of -1.84. The EPS increased by 63.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 2.95% | ||
| ROE | 3.14% | ||
| Debt/Equity | 0 |
CYPH Ownership
CYPH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.02 | 367.796B | ||
| AMGN | AMGEN INC | 15.37 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.19 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.73 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.56 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.41 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CYPH
Company Profile
Cypherpunk Technologies, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2017-01-24. The firm focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
Company Info
IPO: 2017-01-24
CYPHERPUNK TECHNOLOGIES INC
47 Thorndike Street, Suite B1-1
Cambridge MASSACHUSETTS US
Employees: 6
Phone: 18009279800
CYPHERPUNK TECHNOLOGIES INC / CYPH FAQ
What does CYPH do?
Cypherpunk Technologies, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2017-01-24. The firm focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
Can you provide the latest stock price for CYPHERPUNK TECHNOLOGIES INC?
The current stock price of CYPH is 1.06 USD. The price increased by 6.11% in the last trading session.
What is the dividend status of CYPHERPUNK TECHNOLOGIES INC?
CYPH does not pay a dividend.
What is the ChartMill technical and fundamental rating of CYPH stock?
CYPH has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of CYPHERPUNK TECHNOLOGIES INC (CYPH)?
CYPHERPUNK TECHNOLOGIES INC (CYPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.84).